foxo4 dri peptide senolytic 2023 2024 study Development of a novel by precise disruption of FOXO4-p53 complex Peptide inhibitors targeting FOXO4-p53 interactions
Description
This policy option may be difficult to implement
You can read product labels to confirm the product has been authorized for sale by Health Canada
This allows for highly precise dosing and a faster onset of action, which is crucial for studies requiring exact control over compound levels and acute responses
SKU: DIH-TESO-BPC-10-25-125x60 Category: Mind Wellness Research use only The peptides are available for research and laboratory purposes only
